Figure 10From: A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive diseaseTumors with Near-normal and mid-range REST activity levels, show a significant survival benefit from additional chemotherapy. GBM tumors from the TCGA dataset are associated with both outcome and treatment information. Here, we see that additional chemotherapy (4 or more cycles) is associated with significantly increased survival in near-normal and mid-range REST level tumors, but not REM tumors (logrank p<0.02, p<0.01, p=0.262 respectively).Back to article page